arrow
Y

Yaël C. Cohen

Tel Aviv Sourasky Medical Center
H指数:31
被引数:4,885

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states

多发性骨髓瘤的单细胞图谱定义了恶性原型和增殖状态

2026-09-010
PRE
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

达拉妥单抗联合硼替佐米、来那度胺和地塞米松在延迟移植的新诊断多发性骨髓瘤中的应用:CEPHEUS研究中的虚弱亚组分析

Leukemia
IF13.4
2026-08-180
OA
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

多发性骨髓瘤患者寡分泌或非分泌性复发的临床特征与结局—一项回顾性队列研究

2026-04-070
OA
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma

WVT078(一种BCMA×CD3双特异性抗体)在复发和/或难治性多发性骨髓瘤患者中,单独及联合γ-分泌酶抑制剂WHG626的1期剂量递增研究的最终临床数据

Cancer
IF5.1
2026-03-250
PRE
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Cilta-cel 在来那度胺难治性多发性骨髓瘤中的疗效(CARTITUDE-4):一项开放标签、多中心、随机、III期试验的更新分析,包括总生存期数据

2026-01-070
OAAI
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

用Talquetamab和Teclistamab双重靶向髓外骨髓瘤

2025-12-012
PRE
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

CEPHEUS研究的简明语言摘要:达拉木单抗联合硼替佐米、来那度胺和地塞米松,用于预期不接受干细胞移植的新诊断多发性骨髓瘤患者。

2025-10-010
PRE
Preclinical discovery and initial clinical data of WVT078, a BCMA x CD3 bispecific antibody (vol 17, pg 1349, 2023)

WVT078的临床前发现及初步临床数据,一种BCMA x CD3双特异性抗体(卷17,页1349,2023)

LEUKEMIA
IF13.4
2025-05-150
PRE
Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial

功能性老年评估测试可预测接受达鲁珠单抗、卡非佐米、来那度胺和地塞米松治疗的功能性高风险骨髓瘤患者的毒性发生率,在一项前瞻性临床试验中。

BLOOD
IF23.1
2024-11-050
PRE
Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

三药耐药多发性骨髓瘤(MM)患者中Cevostamab的生物标志物相关性及临床活性:这些患者已接受≥1种既往B细胞成熟抗原(BCMA)靶向双特异性抗体(BsAb);结果来自I/II期CAMMA 2研究

BLOOD
IF23.1
2024-11-050
PRE